# For All Organizations

#### Organizational Information

	gal name of your organization? (P nd do not use abbreviations)	lease consult with your general counsel to
-	organization's preferred name (e.ge and accreditation certificates)?	., the name that should appear on
* 3. What is the ad	ldress of your organization?	
Street Address		
Street Address Line 2		
City		
State / Province / Territory		
Country / Region		
Zip/Postal Code		
Location of Rese	earch Activities, Types of Rese	arch, and Regulations Applied
	s human participants research tha r sponsors occur (select all that a	t your organization conducts, reviews, oply)?
Research act	ivities occur in the state/province/region	within the country where the organization is primarily
Research act primarily bas		ions within the country where the organization is
Research act	ivities occur in countries other than the c	ountry where the organization is primarily based
* 5. What kind of r (Select all that app	v s	eview, conduct, manage, and/or sponsor?
	Yes	No
Biomedical / clinical	0	
Social / behavioral / education		

Yes	No		
	0		
	$\bigcirc$		
w, conduct, manage, and/or sponsor p	lanned emergency		
* 8. Does your organization review, conduct, manage, and/or sponsor studies involving any of the following vulnerable participant populations?			
Yes	No		
$\bigcirc$			
$\bigcirc$	$\bigcirc$		
$\bigcirc$			
	$\bigcirc$		
* 9. What type(s) of funding does your organization receive for the review, management, conduct, and/or sponsorship of human participants research?			
Yes	No		
$\bigcirc$			
$\bigcirc$	$\bigcirc$		
0			
	w, conduct, manage, and/or sponsor processed and/or sponsor study populations?  Yes  ur organization receive for the review an participants research?		

\* 6. Does your organization review, conduct, manage, and/or sponsor studies involving any of

research portfolio, whether or not you have open studies that must comply with those regulations? The information helps AAHRPP identify the regulations under which it will evaluate your organization.			
	Yes	No	
US Department of Defense (DoD)	$\circ$		
US Department of Education (ED)	$\circ$		
US Department of Energy (DOE)	$\circ$		
US Department of Health and Human Services (DHHS)			
US Department of Justice (DoJ)	$\circ$		
US Department of Veterans Affairs (VA)	$\bigcirc$		
US Environmental Protection Agency (EPA)	$\circ$		
US Food and Drug Administration (FDA)			
US National Science Foundation (NSF)	$\circ$		
* 11. Does your organization have a US Federalwide Assurance (FWA)?  Yes  No  For organizations with a Federalwide Assurance (FWA):			
* 12. Do you apply:			
The same policies and procedures regardless of funding			
Different but equivalent policies and procedures for some or all research not covered by regulations			
Organizational Information			

\* 10. Which regulations does your organization reasonably expect could apply to your

Harmonisation-Good Clinical Practice Guideline	e (ICH-GCP)?
<ul> <li>My organization does not adhere to ICH-GCP E6.</li> <li>My organization adheres to ICH-GCP only as adopted by the US FDA or country-specific GCP (e.g., Japan GCP) for all applicable clinical trials.</li> </ul>	My organization adheres to ICH-GCP E6 at a sponsor's request but otherwise adheres to ICH-GCP only as adopted by the US FDA or country-specific GCP (e.g., Japan GCP) for all applicable clinical trials.
My organization only adheres to ICH-GCP E6 at a sponsor's request.	My organization adheres to ICH-GCP E6 for all applicable clinical trials.
* 14. Is your organization based primarily in the	e United States?
Yes	
○ No	
Organizations Outside the US	
* 15. What country-specific laws, regulations, and research involving human participants?	guidance does your organization apply to
Independent IRBs/ECs	
* 16. Is your organization an independent IRB/E	EC?
NOTE: An independent IRB/EC is an IRB or ethics comconducts research, and that is <i>not</i> owned or open it provides review services. These organizations IRBs.	erated by the research organization for which
IRBs/ECs embedded within the organization the organizations, hospitals, or health systems) are	•
You can check how AAHRPP classifies your orgainstitute, independent IRB, etc.) at https://www Yes No	-

\* 13. Does your organization reasonably expect to adhere to the International Conference on

For Independent IRBs/ECs

* 17. How many	IRBs or ECs does your o	organization maintain?
<u> </u>		<u> </u>
<u> </u>		<b>7</b>
<u> </u>		8
<u> </u>		<b>9</b>
<u> </u>		<u> </u>
More than 10	(please specify)	
18. Please tell us a	bout the staff for your in	ternal IRBs/ECs:
Total number of FTEs your organization has dedicated to your IRB(s)/EC(s) in the most recent year (the period from January 1 through December 31) or last fiscal year.		
* 19. Please tell us	about your organization	's IRB/EC review of studies:
Number of open studies <b>reviewed via</b> <b>expedited</b> <b>procedures</b> at initial review		
Number of open studies <b>reviewed at a</b> <b>convened IRB/EC</b> <b>meeting</b> at initial review		
Number of exempt human participants research determinations made within the most recent year (the period from January 1 through December 31).		
Note: this includes exemption determinations made using the limited IRB review procedure within the US Common Rule.		

* 20. Please tell us about your IRB's/EC's review of reportable events within the most recent
year (the period from January 1 through December 31):
Number of determinations of serious noncompliance made by your IRB(s)/EC(s)
Number of determinations of continuing noncompliance made by your IRB(s)/EC(s)de
Number of determinations of unanticipated problems made by your IRB(s)/EC(s)
* 21. In the most recent year (the period from January 1 through December 31), what was the number of <b>governmental or regulatory agency</b> (e.g., US FDA, other US regulatory agencies, or other country regulatory agencies) <b>inspections of research studies your organization reviews that resulted in a finding or a request for an official compliance action (e.g., issuance of a US FDA Form 483 or FDA Warning Letter)?</b>
If your organization does not track this information, please indicate this.

$\ast$ 22. Please tell us	about other compliance activities in the most recent year (the period from $% \left( 1\right) =\left( 1\right) \left( 1\right) $
January 1 through	December 31):
Number of "for cause" audits your organization conducted of research studies your organization reviews	
Number of "not for cause"/random/routi ne post-approval audits of research studies your organization reviewed	
Number of governmental or regulatory agency (e.g., US FDA, other US regulatory agencies, or other country regulatory agencies) inspections or reviews of IRB(s)/EC(s)	
Number of "for cause" audits of IRB/EC records/processes conducted internally	
Number of "not for cause"/random audits of IRB/EC records/processes conducted internally	
	about your organization's management of financial conflicts of interest articipants research in the most recent year (the period from January 1 31):
Number of studies with a financial conflict of interest management plan for an initial review of a study or a change in research adding a new management plan reviewed by your organization's IRB(s)/EC(s)	

* 24. Did your IRB(s)/EC(s) approve any studies at initial review at a CONVENED BOARD meeting in the most recent year (the period from January 1 through December 31)?
Yes
○ No
Independent IRB/EC - Convened Board Review Timelines
* 25. For the most recent year (the period from January 1 through December 31), what is the MEDIAN number of calendar days from:
Submission to CONVENED BOARD REVIEW for initial review of human participants research
Submission to final approval via CONVENED BOARD REVIEW for initial review of human participants research
Independent IRB/EC - Expedited Review
* 26. Did your IRB(s)/EC(s) approve any studies at initial review outside a convened meeting (in the US called " <b>expedited review</b> ") in the most recent year (the period from January 1 through December 31)?
Yes
○ No
Independent IRB/EC - Expedited Review Timelines
* 27. For the most recent year (the period from January 1 through December 31), what is the MEDIAN number of calendar days from submission to approval via EXPEDITED REVIEW for initial review of human participants research?

Independent IRB/EC - Exempt Human Participants Research

* 28. Did your IRB(s)/EC(s) determine any studies to be e in the most recent year (the period from January 1 through	
Yes	
○ No	
Independent IRB/EC - Timelines for Exemption Deter	minations
* 29. For the most recent year (the period from January 1 th MEDIAN number of calendar days from submission to an ex	•
. 1 1	
Independent IRB/EC	
30. Please tell us about any electronic (computer) system that apply.	s your IRB(s)/EC(s) uses. Check all
My organization's IRB(s)/EC(s) uses an electronic system	:
	ocument or record IRB/EC decisions and specific determinations within the system.
applications and supporting materials.	oplicable. My IRB(s)/EC(s) does not use any onic (computer) system in support of the
that allows IRB/EC members and staff to communicate about IRB applications and other related materials.	C submission and review process.
* 31. Does your IRB(s)/EC(s) compensate any IRB/EC me	mbers?
Yes	
○ No	For all organizations
	For all organizations
	that are NOT
Use of External IRBs/ECs	independent IRBs/ECs
* 32. Does your organization use one or more external IR human participants research?	Bs/ECs to review some or all of its
Yes	
○ No	

External IRBs/ECs

Please tell us about your organization's use of external IRBs/ECs:

For all organizations that use External IRBs/ECs

* 33. What is the number of open studies (exreviewed by an external IRB(s)/EC(s)	xcluding exempt hum	an participants research)
* 34. Does your organization rely on a <b>no</b> or all of its human participants research?		<b>)/EC(s)</b> for the review of some
Yes, my organization relies on a non-accredit research.	ted IRB(s)/EC(s) for the rev	view of ALL of its human participants
Yes, my organization relies on a non-accredit participants research.	ted IRB(s)/EC(s) for the rev	view of SOME of its human
No, my organization does not rely on any not participants research.	n-accredited IRB(s)/EC(s) f	for the review of its human
		If answered "SOME" in above Q.34
Not AAHRPP-Accredited External Review	ew	III above Q.34
* 35. What is the approximate percentage relied on an external IRB(s)/EC(s) that is recent year (the period from January 1 the content of the	not AAHRPP-accredit	ed for review during the most
<u>26-50</u>		If answered "ALL" in Q.34
Non-AAHRPP Accredited External Revi	iew - All Human Paı	rticipants Research
36. Please provide the name(s) of the non-acorganization relies for the review of ALL of	ccredited IRB(s)/EC(s	) upon which your
External Review Process		

* 37. Please select the statement that best describes your organization process:	's ethical review
My organization relies on one or more external IRB(s)/EC(s) to review ALL of its research, which could include determinations of whether research involving hun research.	
My organization relies on one or more external IRB(s)/EC(s) to review ALL of its research, but not for determinations of whether research involving human partic	
My organization relies on one or more external IRB(s)/EC(s) to review SOME of research, which could include determinations of whether research involving hun research.	
My organization relies on one or more external IRB(s)/EC(s) to review SOME of research, but not for determinations of whether research involving human partic	
Organizations with Internal IRBs/ECs	For all organizations that have internal IRBs/ECs (but are NOT Independent
	IRBs/ECs)
* 38. How many IRBs or ECs does your organization maintain?	
<u>2</u>	
<u>3</u>	
<b>4</b>	
<u> </u>	
<u> </u>	
O 7	
<b>8</b>	
<b>9</b>	
<u> </u>	
More than 10 (please specify)	
* 39. Please tell us about the staff for your internal IRBs/ECs.	
Total number of FTEs your organization has dedicated your IRB(s)/EC(s) in the most recent year (the period from January 1 through December 31)	

\* 40. Please tell us about other compliance activities related to  ${\bf IRB/EC}$  review in the most

facility?
Yes
○ No
Veterans Affairs Academic Affiliate
* 45. Does your organization serve as the academic affiliate for a Veterans Affairs (VA) facility?
○ Yes
○ No
VA Academic Affiliate
* 46. My organization serves as an academic affiliate for the following VA facility(ies):
To. 1-1y organization serves as an academic animate for the following virial may (ies).
Expedited Review
* 47. Do the laws, regulations, codes, and guidance under which your organization conducts or reviews research involving human participants allow research that is not exempt to be reviewed by a non-committee process? Under the US Common Rule this non-committee review process is referred to as <b>expedited review</b> .
Yes
○ No
Expedited Review Process
* 48. What is the number of open studies reviewed by an internal IRB(s)/EC(s) under <b>expedited procedures</b> at initial review?
* 49. Did your IRB(s)/EC(s) approve any studies at initial review under expedited procedures in the most recent year (the period from January 1 through December 31)?
Yes
○ No

\* 44. Does your organization provide IRB review for a US Department of Veterans Affairs

Expedited Review Timeline
* 50. For the most recent year (the period from January 1 through December 31), what was the MEDIAN number of calendar days from submission to approval via EXPEDITED REVIEW for initial review of human participants research?
Convened Board Review
* 51. What is the number of open studies reviewed by an internal IRB(s)/EC(s) at a convened meeting at initial review?
* 52. Did your IRB(s)/EC(s) approve any studies at initial review at a convened board meeting in the most recent year (the period from January 1 through December 31)?  Yes  No
Convened Board Review
* 53. For the most recent year (the period from January 1 through December 31), what was the MEDIAN number of calendar days from:
Submission to CONVENED BOARD REVIEW for initial review of human participants research
Submission to FINAL APPROVAL via convened board review for initial review of human participants research
For ALL organizations that are
Exempt Human Participants Research NOT Independent IRBs/ECs
* 54. Do the laws, regulations, codes, and guidance under which your organization conducts or reviews human participants research allow this research to be determined <b>exempt</b> ?  Yes  No

# Exempt Human Participants Research Determinations \* 55. Please select the statement that best describes your organization's policies and procedures for exempt human participants research. My organization solely allows exempt human participants research determinations as outlined within US regulations. My organization allows exempt human participants research determinations as outlined within US regulations as well as additional categories within institutional policy. My organization does not follow the US Common Rule but allows exempt human participants research determinations as outlined within my country's regulations or my organization's policy. \* 56. What is the number of exempt human participants research determinations made within the most recent year (the period from January 1 through December 31) by an external review process (e.g., by an external IRB/EC)? Note this includes exemption determinations made using the limited IRB review procedure within the US Common Rule. \* 57. Does your organization permit the use of limited IRB review as described in the US Common Rule for exempt human participants research? ( Yes O No \* 58. Does your organization use an internal process to make exempt human participants research determinations? Yes No **Exemption Determinations by Internal Review Process**

59. Were any exemption determinations made within the most recent year (the period from
January 1 through December 31) by an <b>internal review process</b> ? Note this includes
exemption determinations made using the limited IRB review procedure within the US
Common Rule.
Yes

Exemption Determinations by Internal Review Process in most recent year

* 60. What is the n	umber of exempt human participants research determinations made
	cent year (the period from January 1 through December 31) <b>by an</b>
	rocess (e.g., by an internal IRB/EC or other internal HRPP review
<del>-</del>	s includes exemption determinations made using the limited IRB review
	he US Common Rule.
procedure within t	nie 03 Common Rule.
* 61 For exemption	on determinations made through an internal review process (which
<del>-</del>	ew by an IRB/EC) during the most recent year (the period from January 1
	31), what is the MEDIAN number of calendar days from the submission to
=	
an exemption deter	rinination:
Review of Repor	table Events for Organizations that are not Independent IRBs/ECs
* 62 Places tall us	about your organization's review of the following events within the most
	eriod from January 1 through December 31):
_	flod from January 1 through December 31):
Number of	
determinations of serious	
noncompliance,	
including those made	
through your	
organization's review	
process (which could be by an internal	
IRB/EC) and external	
IRB/ECs	
Number of	
determinations of	
continuing	
noncompliance,	
including those made through your	
organization's review	
process (which could	
be by an internal	
IRB/EC) and external	
IRB/ECs	
Number of	
determinations of	
unanticipated	
<b>problems</b> , including those made through	
your organization's	
review process (which	
could be by an internal	
IRB/EC) and external	
IRB/ECs	

$recent\ year\ (the\ period\ from\ January\ 1\ through\ December\ 31)$	
Number of governmental or regulatory agency (e.g., US FDA, other US regulatory agencies, or other country regulatory agencies) inspections of research studies your organization conducted, managed, reviewed, and/or sponsored that resulted in a finding or a request for an official compliance action (e.g., issuance of a US FDA Form 483	
Number of "for cause" audits your organization conducted of research studies that your organization manages, conducts, reviews, and/or sponsors	
Number of "not for cause"/random/routi ne post-approval audits your organization conducted of research studies your organization manages, conducts, reviews, and/or sponsors	
Financial Conflicts of Interest	
* 64. Please tell us about your organization's management of firelated to human participants research in the most recent year through December 31):	
What is the number of studies with a financial conflict of interestinitial review of a study or a change in research adding a new your organization's IRB(s)/EC(s) or external IRB(s)/EC(s)?	_

\* 63. Please tell us about other compliance activities related to  ${f research\ studies}$  in the most

For Organizations that have internal IRBs/ECs or are Independent IRBs/ECs

#### Compensation of IRB/EC Chairs and Vice Chairs

	n internal IRB/EC and is not an independent IRB/EC
Yes	
○ No	
pe of IRB/EC Chair/Vice Chair Compens	ation
* 66. Please indicate any of the following type provides IRB/EC chairs or vice chairs (if your apply)	
Salary support (full or partial)	Support for attendance at HRPP/IRB-related conferences or continuing education activitie
Pay for specific activities (e.g., conducting IRB meetings, reviews)	such as travel or registration fees
Stipend/honorarium	Reimbursement of the IRB/EC chair/vice chair home department/clinic for time
Other, please describe	
ompensation for Affiliated IRB/EC Memb	are Who are not Chaire or Vice Chaire
-	
* 67. Please indicate any of the following type provides for <b>affiliated IRB/EC Members</b> . (C	
Salary support (full or partial)	Support for attendance at HRPP/IRB-related
Pay for specific activities (e.g., attending IRB meetings, reviews)	conferences or continuing education activities such as travel or registration fees
Stipend/honorarium	Reimbursement of the IRB/EC IRB member's home department/clinic for time
Other, please describe	-
_	
My organization does not provide financial	
support for affiliated IRB/EC members.	

Compensation for Unaffiliated IRB/EC Members Who are not Chairs or Vice Chairs

* 68. Please indicate any of the following types provides for <b>unaffiliated IRB/EC members</b> .			
Salary support (full or partial)  Pay for specific activities (e.g., attending IRB	Support for attendance at HRPP/IRB-related conferences or continuing education activities,		
meetings, reviews)	such as travel or registration fees		
Stipend/honorarium			
Other, please describe			
My organization does not provide financial support for unaffiliated IRB/EC members.			
	For All		
	Organizations		
Required Reporting Form	3		
Indicate if any of the following changes have last 12 months by checking the box.	occurred in your Organization in the		
* 69. Organizational Changes			
Change in name of the organization.	Change in the leadership of the Human Research		
Any mergers or acquisitions.	Protection Program (HRPP) (i.e., the individual responsible for the day-to-day operation)		
Change in the organizational official.	Change in the application contact.		
No organizational changes.			
* 70. Please provide a description of any organiza Reporting Form. If you have not had any organiza Applicable".	_		
Required Reporting Form			
Resource Changes			
* 71. Has your organization experienced a charsignificant reduction (10% or more) in resource			
Yes			
○ No			

**Resources Changes Description** 

Required Reporting Form

* 72. Please describe the changes in resources in	the past 12 months.
Required Reporting	
<b>Program Scope Changes</b>	
* 73. Indicate if any of the following Program S occurred in the last year by checking the box.	cope Changes pertaining to your HRPP have
Addition of new research programs (i.e., research no Organization, such as planned emergency research,	ot previously conducted or reviewed by the research involving children, or gene transfer research).
Addition, removal, or modification of functions, com	mittees, or IRBs/ECs.
Changes in organizations that are entities of your H	RPP
No program scope changes.	
Applicable".	
Required Reporting Form  Major Events	
Major Events	
* 75. Indicate if any of the following MAJOR EV	
in your organization in the last year by checkin	S S
reported to AAHRPP within 48 hours after the	organization becomes aware of them.
Catastrophic event that results in an interruption or discontinuance in a component of or the entire HRPP.	Any press coverage (including but not limited to radio, TV, newspaper, online publications) of a negative nature regarding the organization's HRPP.
Any actions by a government oversight office, including but not limited to OHRP Determination Letters, FDA Warning Letters, FDA 483 Inspection Reports with official action indicated, FDA Restrictions placed on IRBs or Researchers, and corresponding compliance actions taken under non-US authorities related to human research protections.	No major reportable events.
Any litigation, arbitration, or settlements initiated related to human research protections.	

76. Did you alrea	ndy report all of the events checked above to AAHRPP?
Yes	
O No	
One of the ab	ove major events occurred in my organization.
Required Reporti	ng Form
<b>Major Events Des</b>	cription
* 77. Please provide	e a summary of the major events that you have not previously reported.
Attestation	
•	nat all of the answers provided on my Annual Report have been
correct.	the application contact and the organizational official and are
	u di A de de
_	eting this Annual Report
Prefix (Professor, Doctor, Mr., Ms., etc.)	
First Name	
L	
Last Name	
Degrees and credentials	
Title	
Email Address	

## \* 79. Application Contact

Prefix (Professor,	
Doctor, Mr., Ms., etc.)	
Doctor, Mr., Ms., etc.)	
Einst Mann	
First Name	
Last Name	
Degrees and	
credentials	
Title	
Department	
•	
Primary Email	
Timary Linan	
43:	
Alternate Email	
Office Phone	
(including country	
code)	
Mailing Street Address	
Street Address Line 2	
City	
,	
State/Province/Territor	
у	
Zip/Postal Code	
Zip/103ta100ac	
0	
Country/Region	
Other Contact (e.g.,	
-	
fax with country code;	
Skype, WeChat, or	
Line ID)	

* 80. Organization	ai Omciai			
Prefix (Professor, Doctor, Mr., Ms., etc.)				
First Name				
Last Name				
Degrees and credentials				
Title				
Department				
Primary Email				
Alternate Email				
Office Phone (including country code)				
Other Contact (e.g., fax with country code; Skype, WeChat, or Line ID)				
Miscellaneous C	omments			
81. Please use this space for additional comments or clarifications.				
		le		

## Congratulations on completing your 2024 Annual Report!

When you are ready to submit your final responses, please click "DONE" below. Once you complete the survey, you will not be able to change your responses.

Please contact reporting@aahrpp.org if you have any questions.